Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(2.89)
# 1,356
Out of 5,182 analysts
110
Total ratings
51.52%
Success rate
7.07%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Downgrades: Neutral | n/a | $0.35 | - | 2 | Mar 23, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6 → $10 | $4.29 | +133.10% | 2 | Feb 4, 2026 | |
| INSM Insmed | Maintains: Overweight | $216 → $230 | $135.98 | +69.14% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.89 | +111.64% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $6.79 | +62.00% | 2 | Oct 30, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $566.99 | -7.41% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $53.81 | +67.27% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $426.01 | +12.67% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $57.78 | -4.81% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $127.75 | -37.38% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $14.74 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $744.44 | +36.34% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $340.18 | +19.05% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $308.51 | -28.69% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $16.37 | -38.91% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $2.63 | +147.15% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $50.99 | +41.20% | 1 | Apr 13, 2023 |
Gossamer Bio
Mar 23, 2026
Downgrades: Neutral
Price Target: n/a
Current: $0.35
Upside: -
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $6 → $10
Current: $4.29
Upside: +133.10%
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $135.98
Upside: +69.14%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.89
Upside: +111.64%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $6.79
Upside: +62.00%
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $566.99
Upside: -7.41%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $53.81
Upside: +67.27%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $426.01
Upside: +12.67%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $57.78
Upside: -4.81%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $127.75
Upside: -37.38%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $14.74
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $744.44
Upside: +36.34%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $340.18
Upside: +19.05%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $308.51
Upside: -28.69%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $16.37
Upside: -38.91%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $2.63
Upside: +147.15%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $50.99
Upside: +41.20%